Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Oppenheimer analyst Steven Lichtman maintains BrainsWay (NASDAQ:BWAY) with a Outperform and raises the price target from $10...
HC Wainwright & Co. analyst Raghuram Selvaraju maintains BrainsWay (NASDAQ:BWAY) with a Buy and raises the price target ...
This would represent growth of 16% to 26% over full-year 2023 revenue. In addition, it continues to anticipate that profitabili...
BrainsWay (NASDAQ:BWAY) reported quarterly sales of $9.095 million which beat the analyst consensus estimate of $8.720 million ...
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasi...
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasiv...
